APA (7th ed.) Citation

Ford, A. C., Wright-Hughes, A., Alderson, S. L., Ow, P., Ridd, M. J., Foy, R., . . . Everitt, H. A. (2023). Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet (British edition), 402(10414), 1773-1785. https://doi.org/10.1016/S0140-6736(23)01523-4

Chicago Style (17th ed.) Citation

Ford, Alexander C., et al. "Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care (ATLANTIS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet (British Edition) 402, no. 10414 (2023): 1773-1785. https://doi.org/10.1016/S0140-6736(23)01523-4.

MLA (9th ed.) Citation

Ford, Alexander C., et al. "Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care (ATLANTIS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet (British Edition), vol. 402, no. 10414, 2023, pp. 1773-1785, https://doi.org/10.1016/S0140-6736(23)01523-4.